Biotechnology Soon To Be Acquired Cerevel Therapeutics Reveals High Level Data From Late-Stage Parkinson’s Disease Study – Cerevel Therapeutics Hldg (NASDAQ:CERE) Read more
Biotechnology AbbVie Lifts Long-Term Outlook For New Immunology Drugs, Even As Q4 Revenue and Profit Fall – Cerevel Therapeutics Hldg (NASDAQ:CERE), AbbVie (NYSE:ABBV) Read more
Biotechnology AbbVie’s Transformational 2023, Analyst Anticipates Growth in 2024 Amid Competitive Pressures – Cerevel Therapeutics Hldg (NASDAQ:CERE), AbbVie (NYSE:ABBV) Read more
